Abl (Q252H), active 14-751M from DiscoverX

Description

N-terminal His6-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125)

Product Specs
ItemAbl (Q252H), active
CompanyDiscoverX
Price $2,467.00Supplier Page View Company Product Page
Catalog Number14-751M
Size250 µg
Activityactive
ApplicationsKinase Assay
ConcentrationSee COA
Conjugate/TagHis6
FormatProtein in 50 mM Tris/HCl pH7.5, 150 mM NaCl, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution
TypeKinase
Molecular Weight121kDa
SpeciesHuman
Molecule NameAbl
Source/Expression SystemExpressed by baculovirus in Sf21 insect cells
NCBI Full Gene NameABL proto-oncogene 1, non-receptor tyrosine kinase
NCBI Gene AliasesABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl
Research AreaCell Signaling